Weifeng Ding
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Weifeng Ding has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
Jianfeng Zhang
Department of Gastroenterology, Affiliated Hospital of Nantong University, Medical school of Nantong University, Nantong, 226001, Jiangsu Province, China
6 shared publicationsWeilin Pu
Greater Bay Area Institute of Precision Medicine (Guangzhou), School of Life Sciences, Fudan University, Guangzhou 511458, China
6 shared publicationsFei Qian
Department of Laboratory Medicine; Department of Gastrointestinal Surgery, Affiliated Hospital of Nantong University, Medical school of Nantong University, Nantong 226001, Jiangsu Province, China
5 shared publications- Jianfeng Zhang
Department of Laboratory Medicine; Department of Gastroenterology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China
4 shared publications Keke Shao
Department of Laboratory Medicine, The Yancheng Clinical College of Xuzhou Medical University, The First people's Hospital of Yancheng, Yancheng, China; Molecular Medical Research Center, Yancheng Clinical Medical College of Jiangsu University, Yancheng, China
4 shared publicationsShicheng Guo
Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, China
4 shared publications
Latest Publications
- Open Access
- 19 December 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (51) , e46637
MICA-129 Met/Met contributes to the susceptibility of colorectal cancer
The highly polymorphic human major histocompatibility complex class I chain-related gene A (MICA) regulates immune surveillance and destroys tumor cells by activating its receptor, the natural killer group 2D. This study aimed to examine a single nucleotide polymorphism of this gene at codon 129 (MICA-129) in association with colorectal cancer (CRC). Using PCR sequencing, the MICA-129 polymorphism was examined in 104 patients with CRC and 536 healthy controls. Specific MICA-129 single nucleotide polymorphism was analyzed for its association with CRC susceptibility, clinical phenotypes, and selected CRC-associated microsatellite instability, driver gene mutation, immune checkpoint programmed death ligand 1, and diagnostic biomarkers carbohydrate antigen 19-9 and carcinoembryonic antigen. The MICA-129 heterozygous A/G (Met/Val) genotype was associated with less aggressive clinical characteristics, such as a reduced prevalence of the ulcerated subtype ( P = .0489, OR = 0.59) and lymph node involvement ( P = .0217, OR = 0.46). Conversely, the MICA-129 homozygous allele A/A (Met/Met) variant was related to more advanced clinical characteristics, such as increased tumor invasion depth (T3/4; P = .0261, OR = 2.10), driver gene mutation ( P = .0363, OR = 2.65), and KRAS mutation ( P = .0392, OR = 2.23). Additionally, patients with carbohydrate antigen 19-9-positive CRC had a lower MICA-129 Met/Val variation, whereas those with carcinoembryonic antigen-positive CRC had a higher MICA-129 Met/Met variant ( P = .0330/OR = 0.22 and P = .0034/OR = 2.99, respectively).
- 19 December 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (51) , e46637
Open AccessMICA-129 Met/Met contributes to the susceptibility of colorectal cancer
The highly polymorphic human major histocompatibility complex class I chain-related gene A (MICA) regulates immune surveillance and destroys tumor cells by activating its receptor, the natural killer group 2D. This study aimed to examine a single nucleotide polymorphism of this gene at codon 129 (MICA-129) in association with colorectal cancer (CRC). Using PCR sequencing, the MICA-129 polymorphism was examined in 104 patients with CRC and 536 healthy controls. Specific MICA-129 single nucleotide polymorphism was analyzed for its association with CRC susceptibility, clinical phenotypes, and selected CRC-associated microsatellite instability, driver gene mutation, immune checkpoint programmed death ligand 1, and diagnostic biomarkers carbohydrate antigen 19-9 and carcinoembryonic antigen. The MICA-129 heterozygous A/G (Met/Val) genotype was associated with less aggressive clinical characteristics, such as a reduced prevalence of the ulcerated subtype ( P = .0489, OR = 0.59) and lymph node involvement ( P = .0217, OR = 0.46). Conversely, the MICA-129 homozygous allele A/A (Met/Met) variant was related to more advanced clinical characteristics, such as increased tumor invasion depth (T3/4; P = .0261, OR = 2.10), driver gene mutation ( P = .0363, OR = 2.65), and KRAS mutation ( P = .0392, OR = 2.23). Additionally, patients with carbohydrate antigen 19-9-positive CRC had a lower MICA-129 Met/Val variation, whereas those with carcinoembryonic antigen-positive CRC had a higher MICA-129 Met/Met variant ( P = .0330/OR = 0.22 and P = .0034/OR = 2.99, respectively).
- 1 November 2025
- Published by Elsevier in Cellular Signalling
- Vol. 138, 112197
Single-cell sequencing analysis reveals CHURC1 as a non-canonical oncoprotein governing goblet cell-driven colorectal tumorigenesis
- 1 November 2025
- Published by Elsevier in Cellular Signalling
- Vol. 138, 112197
Single-cell sequencing analysis reveals CHURC1 as a non-canonical oncoprotein governing goblet cell-driven colorectal tumorigenesis
- Open Access
- 9 July 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-12
M6A-METTL3-dependent nuclear PANC754/PSPC1/H3K4me1 repression complex regulate immune evasive LGALS7 signal to enhance immunotherapy against colorectal cancer
Non-coding RNAs (ncRNAs) have important regulatory functions similar to traditional oncogenes or tumor suppressor genes. Our previous research found a novel pan-cancer downexpressed ncRNA, PANC754. However, its function and underlying mechanism remain obscure in colorectal cancer (CRC). In this study, in vitro and in vivo experiments were performed to determine the function of PANC754. Loss and gain of function experiments, molecular docking experiments, and bioinformatic analysis were utilized to visualize its pathway. Co-culture system was leveraged to explore its effect on synergetic immune checkpoint blockage against CRC. Through a series of studies, we found that overexpressed PANC754 significantly inhibited cell viability, migration, and metastasis and induced notable apoptosis in CRC. The mechanical research found that PANC754 was the nuclear-located and its expression was regulated by m6A modification via METTL3 enzyme, which bound with its RBP PSPC1, then interacted with H3K4me1 to chromatin-accessible inhibit immune evasive molecule LGALS7 and led to suppress CRC progress. Furthermore, we confirmed that prominent upregulation of the immune checkpoint inhibitory (ICI) capability of anti-NKG2A, monalizumab when it was combined with PANC754 overexpression. Collectively, our study revealed that PANC754 is a tumor-suppressing ncRNA to form an ncRNA/RBP/histone repression complex with m6A-dependence, which can enhance the immune therapeutics effect of ICI, suggesting a promising therapeutic target.
- 9 July 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1) , 1-12
Open AccessM6A-METTL3-dependent nuclear PANC754/PSPC1/H3K4me1 repression complex regulate immune evasive LGALS7 signal to enhance immunotherapy against colorectal cancer
Non-coding RNAs (ncRNAs) have important regulatory functions similar to traditional oncogenes or tumor suppressor genes. Our previous research found a novel pan-cancer downexpressed ncRNA, PANC754. However, its function and underlying mechanism remain obscure in colorectal cancer (CRC). In this study, in vitro and in vivo experiments were performed to determine the function of PANC754. Loss and gain of function experiments, molecular docking experiments, and bioinformatic analysis were utilized to visualize its pathway. Co-culture system was leveraged to explore its effect on synergetic immune checkpoint blockage against CRC. Through a series of studies, we found that overexpressed PANC754 significantly inhibited cell viability, migration, and metastasis and induced notable apoptosis in CRC. The mechanical research found that PANC754 was the nuclear-located and its expression was regulated by m6A modification via METTL3 enzyme, which bound with its RBP PSPC1, then interacted with H3K4me1 to chromatin-accessible inhibit immune evasive molecule LGALS7 and led to suppress CRC progress. Furthermore, we confirmed that prominent upregulation of the immune checkpoint inhibitory (ICI) capability of anti-NKG2A, monalizumab when it was combined with PANC754 overexpression. Collectively, our study revealed that PANC754 is a tumor-suppressing ncRNA to form an ncRNA/RBP/histone repression complex with m6A-dependence, which can enhance the immune therapeutics effect of ICI, suggesting a promising therapeutic target.
- Open Access
- 16 January 2024
- Published by Open Exploration Publishing in Exploration of Targeted Anti-tumor Therapy
- Vol. 5 (1) , 34-53
DNA methylation modulates epigenetic regulation in colorectal cancer diagnosis, prognosis and precision medicine
Colorectal cancer (CRC) is a multifaceted disease influenced by the interplay of genetic and environmental factors. The clinical heterogeneity of CRC cannot be attributed exclusively to genetic diversity and environmental exposures, and epigenetic markers, especially DNA methylation, play a critical role as key molecular markers of cancer. This review compiles a comprehensive body of evidence underscoring the significant involvement of DNA methylation modifications in the pathogenesis of CRC. Moreover, this review explores the potential utility of DNA methylation in cancer diagnosis, prognostics, assessment of disease activity, and prediction of drug responses. Recognizing the impact of DNA methylation will enhance the ability to identify distinct CRC subtypes, paving the way for personalized treatment strategies and advancing precision medicine in the management of CRC.
- 16 January 2024
- Published by Open Exploration Publishing in Exploration of Targeted Anti-tumor Therapy
- Vol. 5 (1) , 34-53
Open AccessDNA methylation modulates epigenetic regulation in colorectal cancer diagnosis, prognosis and precision medicine
Colorectal cancer (CRC) is a multifaceted disease influenced by the interplay of genetic and environmental factors. The clinical heterogeneity of CRC cannot be attributed exclusively to genetic diversity and environmental exposures, and epigenetic markers, especially DNA methylation, play a critical role as key molecular markers of cancer. This review compiles a comprehensive body of evidence underscoring the significant involvement of DNA methylation modifications in the pathogenesis of CRC. Moreover, this review explores the potential utility of DNA methylation in cancer diagnosis, prognostics, assessment of disease activity, and prediction of drug responses. Recognizing the impact of DNA methylation will enhance the ability to identify distinct CRC subtypes, paving the way for personalized treatment strategies and advancing precision medicine in the management of CRC.
- RetractionOpen Access
- 17 October 2022
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 478 (2) , 429
Retraction Note: Targeting of colorectal cancer growth, metastasis, and anti-apoptosis in BALB/c nude mice via APRIL siRNA
- 17 October 2022
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 478 (2) , 429
RetractionOpen AccessRetraction Note: Targeting of colorectal cancer growth, metastasis, and anti-apoptosis in BALB/c nude mice via APRIL siRNA
- Open Access
- 28 October 2021
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 9
Targeted Bisulfite Sequencing Reveals DNA Methylation Changes in Zinc Finger Family Genes Associated With KRAS Mutated Colorectal Cancer
Background: Colorectal cancer (CRC) is a leading cause of cancer death, and early diagnosis of CRC could significantly reduce its mortality rate. Previous studies suggest that the DNA methylation status of zinc finger genes (ZFGs) could be of potential in CRC early diagnosis. However, the comprehensive evaluation of ZFGs in CRC is still lacking.Methods: We first collected 1,426 public samples on genome-wide DNA methylation, including 1,104 cases of CRC tumors, 54 adenomas, and 268 para-tumors. Next, the most differentially methylated ZFGs were identified and validated in two replication cohorts comprising 218 CRC patients. Finally, we compared the prediction capabilities between the ZFGs and the SEPT9 in all CRC patients and the KRAS + and KRAS- subgroup.Results: Five candidate ZFGs were selected: ESR1, ZNF132, ZNF229, ZNF542, and ZNF677. In particular, ESR1 [area under the curve (AUC) = 0.91] and ZNF132 (AUC = 0.93) showed equivalent or better diagnostic capability for CRC than SEPT9 (AUC = 0.91) in the validation dataset, suggesting that these two ZFGs might be of potential for CRC diagnosis in the future. Furthermore, we performed subgroup analysis and found a significantly higher diagnostic capability in KRAS + (AUC ranged from 0.97 to 1) than that in KRAS- patients (AUC ranged from 0.74 to 0.86) for all these five ZFGs, suggesting that these ZFGs could be ideal diagnostic markers for KRAS mutated CRC patients.Conclusion: The methylation profiles of the candidate ZFGs could be potential biomarkers for the early diagnosis of CRC, especially for patients carrying KRAS mutations.
- 28 October 2021
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 9
Open AccessTargeted Bisulfite Sequencing Reveals DNA Methylation Changes in Zinc Finger Family Genes Associated With KRAS Mutated Colorectal Cancer
Background: Colorectal cancer (CRC) is a leading cause of cancer death, and early diagnosis of CRC could significantly reduce its mortality rate. Previous studies suggest that the DNA methylation status of zinc finger genes (ZFGs) could be of potential in CRC early diagnosis. However, the comprehensive evaluation of ZFGs in CRC is still lacking.Methods: We first collected 1,426 public samples on genome-wide DNA methylation, including 1,104 cases of CRC tumors, 54 adenomas, and 268 para-tumors. Next, the most differentially methylated ZFGs were identified and validated in two replication cohorts comprising 218 CRC patients. Finally, we compared the prediction capabilities between the ZFGs and the SEPT9 in all CRC patients and the KRAS + and KRAS- subgroup.Results: Five candidate ZFGs were selected: ESR1, ZNF132, ZNF229, ZNF542, and ZNF677. In particular, ESR1 [area under the curve (AUC) = 0.91] and ZNF132 (AUC = 0.93) showed equivalent or better diagnostic capability for CRC than SEPT9 (AUC = 0.91) in the validation dataset, suggesting that these two ZFGs might be of potential for CRC diagnosis in the future. Furthermore, we performed subgroup analysis and found a significantly higher diagnostic capability in KRAS + (AUC ranged from 0.97 to 1) than that in KRAS- patients (AUC ranged from 0.74 to 0.86) for all these five ZFGs, suggesting that these ZFGs could be ideal diagnostic markers for KRAS mutated CRC patients.Conclusion: The methylation profiles of the candidate ZFGs could be potential biomarkers for the early diagnosis of CRC, especially for patients carrying KRAS mutations.
- Open Access
- 23 April 2021
- Published by Springer Nature in Clinical Epigenetics
- Vol. 13 (1) , 1-18
DNA hypermethylation contributes to colorectal cancer metastasis by regulating the binding of CEBPB and TFCP2 to the CPEB1 promoter
Background: Aberrant DNA methylation has been firmly established as a factor contributing to the pathogenesis of colorectal cancer (CRC) via its capacity to silence tumour suppressor genes. However, the methylation status of multiple tumour suppressor genes and their roles in promoting CRC metastasis are not well characterised. Methods: We explored the methylation and expression profiles of CPEB1 (the gene encoding cytoplasmic polyadenylation element-binding protein 1), a candidate CRC tumour suppressor gene, using The Cancer Genome Atlas (TCGA) database and validated these results in both CRC cell lines and cells from Han Chinese CRC patients (n = 104). The functional role of CPEB1 in CRC was examined in experiments performed in vitro and in vivo. A candidate transcription factor capable of regulating CPEB1 expression was predicted in silico and validated by luciferase reporter, DNA pull-down, and electrophoretic mobility shift assays. Results: Hypermethylation and decreased expression of CPEB1 in CRC tumour tissues were revealed by TCGA database. We also identified a significant inverse correlation (Pearson’s R = − 0.43, P < 0.001) between promoter methylation and CPEB1 expression. We validated these results in CRC samples and two CRC cell lines. We also demonstrated that up-regulation of CPEB1 resulted in significantly decreased tumour growth, migration, invasion, and tumorigenicity and promoted tumour cell apoptosis both in vitro and in vivo. We identified the transcription factors CCAAT enhancer-binding protein beta (CEBPB) and transcription factor CP2 (TFCP2) as critical regulators of CPEB1 expression. Hypermethylation of the CPEB1 promoter resulted in a simultaneous increase in the capacity for TFCP2 binding and a decreased likelihood of CEBPB binding, both of which led to diminished expression of CPEB1. Conclusions: Our results identified a novel tumour-suppressive role of CPEB1 in CRC and found that hypermethylation of the CPEB1 promoter may lead to diminished expression due to decreased chromatin accessibility and transcription factor binding. Collectively, these results suggest a potential role for CPEB1 in the diagnosis and treatment of CRC.
- 23 April 2021
- Published by Springer Nature in Clinical Epigenetics
- Vol. 13 (1) , 1-18
Open AccessDNA hypermethylation contributes to colorectal cancer metastasis by regulating the binding of CEBPB and TFCP2 to the CPEB1 promoter
Background: Aberrant DNA methylation has been firmly established as a factor contributing to the pathogenesis of colorectal cancer (CRC) via its capacity to silence tumour suppressor genes. However, the methylation status of multiple tumour suppressor genes and their roles in promoting CRC metastasis are not well characterised. Methods: We explored the methylation and expression profiles of CPEB1 (the gene encoding cytoplasmic polyadenylation element-binding protein 1), a candidate CRC tumour suppressor gene, using The Cancer Genome Atlas (TCGA) database and validated these results in both CRC cell lines and cells from Han Chinese CRC patients (n = 104). The functional role of CPEB1 in CRC was examined in experiments performed in vitro and in vivo. A candidate transcription factor capable of regulating CPEB1 expression was predicted in silico and validated by luciferase reporter, DNA pull-down, and electrophoretic mobility shift assays. Results: Hypermethylation and decreased expression of CPEB1 in CRC tumour tissues were revealed by TCGA database. We also identified a significant inverse correlation (Pearson’s R = − 0.43, P < 0.001) between promoter methylation and CPEB1 expression. We validated these results in CRC samples and two CRC cell lines. We also demonstrated that up-regulation of CPEB1 resulted in significantly decreased tumour growth, migration, invasion, and tumorigenicity and promoted tumour cell apoptosis both in vitro and in vivo. We identified the transcription factors CCAAT enhancer-binding protein beta (CEBPB) and transcription factor CP2 (TFCP2) as critical regulators of CPEB1 expression. Hypermethylation of the CPEB1 promoter resulted in a simultaneous increase in the capacity for TFCP2 binding and a decreased likelihood of CEBPB binding, both of which led to diminished expression of CPEB1. Conclusions: Our results identified a novel tumour-suppressive role of CPEB1 in CRC and found that hypermethylation of the CPEB1 promoter may lead to diminished expression due to decreased chromatin accessibility and transcription factor binding. Collectively, these results suggest a potential role for CPEB1 in the diagnosis and treatment of CRC.
- Open Access
- 26 May 2020
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 11, 511
MICA ∗012:01 Allele Facilitates the Metastasis of KRAS-Mutant Colorectal Cancer
Major histocompatibility complex (HLA) class I chain-related protein A (MICA) regulates immune surveillance through activation of NKG2D (natural killer group 2D) receptor. However, the genetic association, potential function, and predictive ability of MICA alleles with colorectal cancer (CRC) prognosis remain undefined. In this study, we characterized MICA alleles in tissue samples from 104 patients with CRC and 536 healthy controls and carried out genetic association studies by molecular and clinical CRC phenotypes. Preliminary sequence analysis revealed that MICA *009:01 or *049 alleles were significantly decreased in patients with CRC (p=0.0049), and further stratification analysis indicated that MICA *012:01 allele was associated with patients with CRC and carrying KRAS codon 12 mutation (p=0.027). The functional consequences of MICA alleles were examined via transfected CRC cell lines which showed that overexpression of MICA *012:01 enhanced the proliferation, invasion, and metastatic phenotype of CRC. Preliminary analysis of disease-free survival time in patients with and without MICA *012:01 suggest this allele may be predictive for poor prognosis of patients with KRAS codon 12 mutated CRC, as no somatic mutation of MICA gene was detected in CRC tumors compared to paracancerous tissues. Our study indicates that MICA *012:01 allele is associated with KRAS-mutated CRC, facilitates CRC invasion and metastasis, and possibly reduces the survival of patients with KRAS-mutated CRC.
- 26 May 2020
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 11, 511
Open AccessMICA ∗012:01 Allele Facilitates the Metastasis of KRAS-Mutant Colorectal Cancer
Major histocompatibility complex (HLA) class I chain-related protein A (MICA) regulates immune surveillance through activation of NKG2D (natural killer group 2D) receptor. However, the genetic association, potential function, and predictive ability of MICA alleles with colorectal cancer (CRC) prognosis remain undefined. In this study, we characterized MICA alleles in tissue samples from 104 patients with CRC and 536 healthy controls and carried out genetic association studies by molecular and clinical CRC phenotypes. Preliminary sequence analysis revealed that MICA *009:01 or *049 alleles were significantly decreased in patients with CRC (p=0.0049), and further stratification analysis indicated that MICA *012:01 allele was associated with patients with CRC and carrying KRAS codon 12 mutation (p=0.027). The functional consequences of MICA alleles were examined via transfected CRC cell lines which showed that overexpression of MICA *012:01 enhanced the proliferation, invasion, and metastatic phenotype of CRC. Preliminary analysis of disease-free survival time in patients with and without MICA *012:01 suggest this allele may be predictive for poor prognosis of patients with KRAS codon 12 mutated CRC, as no somatic mutation of MICA gene was detected in CRC tumors compared to paracancerous tissues. Our study indicates that MICA *012:01 allele is associated with KRAS-mutated CRC, facilitates CRC invasion and metastasis, and possibly reduces the survival of patients with KRAS-mutated CRC.